GEMCITABINE HETERO gemcitabine (as hydrochloride) 200 mg powder for injection vial

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

gemcitabine hydrochloride, Quantity: 228 mg

Pieejams no:

Hetero Australia Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

Gemcitabine hydrochloride

Zāļu forma:

Injection, powder for

Kompozīcija:

Excipient Ingredients: sodium hydroxide; mannitol; sodium acetate trihydrate

Ievadīšanas:

Intravenous Infusion

Vienības iepakojumā:

1 vial

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Produktu pārskats:

Visual Identification: White to off-white lyophilised powder to be reconstituted for intravenous use.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2015-03-03